Skip to main content
Premium Trial:

Request an Annual Quote

We're All for New 'Omes, But a Diseasome? Really?

An article in the New York Times looks at how the field of nosology, or disease classification, is advancing in the face of 'omics research. Stanford's Atul Butte (one of the young investigators profiled in the December 2006/Jaunary 2007 "Tomorrow's PIs" issue of Genome Technology) has been using gene expression profiling to categorize diseases based on genetic activity. Last year, researchers created a map called the "diseasome," which links diseases with the genes associated with them. The story quotes Todd Golub as saying, "In the not too distant future, we will think about these diseases based on the molecular pathways that are aberrant, rather than the anatomical origin of the tumor."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.